CN113348166A - 喹啉衍生物的结晶 - Google Patents

喹啉衍生物的结晶 Download PDF

Info

Publication number
CN113348166A
CN113348166A CN202080011103.1A CN202080011103A CN113348166A CN 113348166 A CN113348166 A CN 113348166A CN 202080011103 A CN202080011103 A CN 202080011103A CN 113348166 A CN113348166 A CN 113348166A
Authority
CN
China
Prior art keywords
crystals
crystal
compound
formula
diffraction peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080011103.1A
Other languages
English (en)
Inventor
张喜全
王善春
耿文军
刘彦龙
张慧慧
刘飞
朱善良
李新路
赵锐
顾红梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN113348166A publication Critical patent/CN113348166A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本申请涉及医药领域，涉及喹啉衍生物的结晶，具体涉及喹啉衍生物无水物、溶剂合物的结晶，以及所述结晶的制备方法、含所述结晶的药物组合物和在医药领域的用途。本申请还提供其制备方法，收率高，结晶条件温和，适合工业化生产，能够更好地满足制药业需求。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080011103.1A 2019-01-31 2020-01-31 喹啉衍生物的结晶 Pending CN113348166A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910095975X 2019-01-31
CN201910095975.XA CN109748904A (zh) 2019-01-31 2019-01-31 喹啉衍生物的结晶
PCT/CN2020/074085 WO2020156501A1 (zh) 2019-01-31 2020-01-31 喹啉衍生物的结晶

Publications (1)

Publication Number Publication Date
CN113348166A true CN113348166A (zh) 2021-09-03

Family

ID=66407264

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910095975.XA Pending CN109748904A (zh) 2019-01-31 2019-01-31 喹啉衍生物的结晶
CN202080011103.1A Pending CN113348166A (zh) 2019-01-31 2020-01-31 喹啉衍生物的结晶

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910095975.XA Pending CN109748904A (zh) 2019-01-31 2019-01-31 喹啉衍生物的结晶

Country Status (4)

Country Link
US (1) US20220098172A1 (zh)
EP (1) EP3919485A4 (zh)
CN (2) CN109748904A (zh)
WO (1) WO2020156501A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109748904A (zh) * 2019-01-31 2019-05-14 正大天晴药业集团股份有限公司 喹啉衍生物的结晶
CN112294813A (zh) * 2019-07-30 2021-02-02 正大天晴药业集团股份有限公司 喹啉衍生物在治疗脊索瘤中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102344438A (zh) * 2010-08-01 2012-02-08 江苏正大天晴药业股份有限公司 喹啉衍生物的结晶及其制备方法
CN107771078A (zh) * 2015-05-04 2018-03-06 爱德程医药有限公司 用于制备抗癌剂1‑((4‑(4‑氟‑2‑甲基‑1h‑吲哚‑5‑基氧基)‑6‑甲氧基喹啉‑7‑基氧基)甲基)环丙胺、其结晶形式和其盐的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
CN103664890B (zh) * 2010-08-01 2016-10-05 正大天晴药业集团股份有限公司 喹啉衍生物的结晶及制备方法
CN105311030B (zh) * 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105213394B (zh) * 2014-06-06 2019-04-09 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
CN114716410A (zh) * 2018-02-11 2022-07-08 正大天晴药业集团股份有限公司 喹啉衍生物的结晶
CN110339195A (zh) * 2018-04-02 2019-10-18 正大天晴药业集团股份有限公司 用于治疗胆管癌的喹啉衍生物
CN109748904A (zh) * 2019-01-31 2019-05-14 正大天晴药业集团股份有限公司 喹啉衍生物的结晶

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102344438A (zh) * 2010-08-01 2012-02-08 江苏正大天晴药业股份有限公司 喹啉衍生物的结晶及其制备方法
CN107771078A (zh) * 2015-05-04 2018-03-06 爱德程医药有限公司 用于制备抗癌剂1‑((4‑(4‑氟‑2‑甲基‑1h‑吲哚‑5‑基氧基)‑6‑甲氧基喹啉‑7‑基氧基)甲基)环丙胺、其结晶形式和其盐的方法

Also Published As

Publication number Publication date
CN109748904A (zh) 2019-05-14
EP3919485A1 (en) 2021-12-08
WO2020156501A1 (zh) 2020-08-06
EP3919485A4 (en) 2022-10-26
US20220098172A1 (en) 2022-03-31
WO2020156501A8 (zh) 2021-08-12

Similar Documents

Publication Publication Date Title
JP2020002168A (ja) マクロライドの結晶形、およびその使用
CN111187253B (zh) 一种阿昔替尼新晶型
KR20120051702A (ko) Ｎ-〔３-플루오로-４-(｛６-(메틸옥시)-７-〔(３-모르폴린-４-일프로필)옥시〕퀴놀린-４-일｝옥시)페닐〕-ｎ''-(４-플루오로페닐)시클로프로판-１,１-디카르복사미드의 결정형
JP6717947B2 (ja) キナゾリン誘導体の結晶及びその調製方法
JP2013522232A (ja) Ｎ−［３−フルオロ−４−（｛６−（メチロキシ）−７−［（３−モルホリン−４−イルプロピル）オキシ］−キノリン−４−イル｝オキシ）フェニル］−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボサミドの水和結晶性形状
CN113348166A (zh) 喹啉衍生物的结晶
CN107955019A (zh) 一种egfr抑制剂的盐型、晶型及其制备方法
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
WO2016079313A1 (en) Crystalline forms of afatinib dimaleate
BR112020026052A2 (pt) forma de cristal do composto para a inibição da atividade de cdk4/6 e seu uso
AU2018252643A1 (en) Compound of EOC315 Mod.I crystal form and preparation method therefor
US20160304504A1 (en) Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl -2-thienyl)-1-phthalazinamine salts and uses thereof
TWI706949B (zh) (３-胺基-環氧丙-３-基甲基)-[２-(５,５-二氧-５,６,７,９-四氫-５入*６*-硫-８-氮雜-苯并環庚烯-８-基)-６-甲基-喹唑啉-４-基]-胺之新穎晶形
WO2021147996A1 (zh) 一种芳胺基嘌呤衍生物的盐及其制备方法和应用
CN111630045A (zh) 喹啉衍生物的结晶
JP2018538348A (ja) キナゾリン誘導体の結晶及びその調製方法
WO2021238835A1 (zh) (2e)-n-[4-[(3-氯-4-氟苯基)氨基]-7-甲氧基-6-喹唑啉基]-4-(1-哌啶基)-2-丁烯酰胺的晶型及其制备方法
TW201833112A (zh) 化合物的晶型
WO2023109776A1 (zh) 一种fgfr4抑制剂酸式盐及其制备方法和应用
Odendaal Artesunate-An investigation into polymorphism
JP2023543055A (ja) テガビビントの結晶形態、調製方法、及びその使用
WO2023283206A1 (en) Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof
CN116854694A (zh) [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用
CN111918869A (zh) 甘草酸衍生物的结晶、其结晶组合物、药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination